Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 14, 2020

View Archived Issues

Phase I/II data presented for the SIIPL-PCV vaccine candidate

MRAP2 is accessory after the fact for appetite regulation

Human proteomics study gives new AD insights

Sanifit opens enrollment in phase III study of SNF-472 for calciphylaxis

Novartis opens phase III study of TQJ-230 in patients with cardiovascular disease

Oncolytic viruses 'wrapped' with tumor cell membranes show improved infectivity in cancer cells

Stem cell-based approach to spinal cord injuries developed

AMO Pharma opens enrollment in pivotal trial of AMO-02 for congenital myotonic dystrophy

BioMarin to initiate clinical testing of BMN-307 gene therapy

New preclinical data support PBI-05204 as a potential treatment for GBM

Topline data presented from TRILOGY 1 study of CaPre

RNF208 as a prognostic biomarker in TNBC

PTC Therapeutics describes new compounds for treating Huntington's disease

Jacobio-Beta Pharmaceuticals, Beijing Jacobio Pharmaceuticals patent BET inhibitors

Remdesivir as a potential new therapeutic option for MERS-CoV

Methylphenidate improves executive functioning in patients with VCI

MSD KK receives approval for Pifeltro for treating HIV-1 infection

New cardiac sarcomere inhibitors discovered at Cytokinetics

Zhejiang Vimgreen Pharma discloses adenosine A2A receptor antagonists

FDA clears IND for phase Ib/II study of AVB-500 in clear cell renal cell carcinoma

FDA approves Valtoco as acute treatment for seizures

Abeona initiates phase III study of EB-101 in recessive dystrophic epidermolysis bullosa

Neos studies NT-0502 in pilot phase I trial for chronic sialorrhea

Lilly opens enrollment in phase I study of CD73 inhibitor LY-3475070 in advanced cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...